Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
Synaffix, a Lonza company, has entered into a license agreement with Mitsubishi Tanabe Pharma (MTPC) for the development of a single ADC program. The agreement includes the use of Synaffix's proprietary GlycoConnect®, HydraSpace®, and toxSYN® ADC technologies, aimed at enhancing efficacy, tolerability, and target engagement.
Under the terms of the agreement, Synaffix will manufacture components related to its proprietary technologies, while MTPC will be responsible for research, development, manufacturing, and commercialization of the ADC. This collaboration expands Synaffix's presence in the APAC region and aims to address areas of high unmet medical needs.
Synaffix, azienda di Lonza, ha stipulato un accordo di licenza con Mitsubishi Tanabe Pharma (MTPC) per lo sviluppo di un programma ADC unico. L'accordo comprende l'utilizzo delle tecnologie ADC proprietarie di Synaffix, GlycoConnect®, HydraSpace® e toxSYN®, mirate a migliorare l'efficacia, la tollerabilità e l'interazione con gli obiettivi terapeutici.
Secondo i termini dell'accordo, Synaffix produrrà i componenti relativi alle sue tecnologie proprietarie, mentre MTPC sarà responsabile della ricerca, dello sviluppo, della produzione e della commercializzazione dell'ADC. Questa collaborazione espande la presenza di Synaffix nella regione APAC e punta a soddisfare aree di elevato bisogno medico insoddisfatto.
Synaffix, una empresa de Lonza, ha firmado un acuerdo de licencia con Mitsubishi Tanabe Pharma (MTPC) para el desarrollo de un único programa de ADC. El acuerdo incluye el uso de las tecnologías de ADC patentadas de Synaffix, GlycoConnect®, HydraSpace® y toxSYN®, con el objetivo de mejorar la eficacia, la tolerabilidad y el compromiso con el objetivo.
Bajo los términos del acuerdo, Synaffix fabricará los componentes relacionados con sus tecnologías patentadas, mientras que MTPC será responsable de la investigación, el desarrollo, la fabricación y la comercialización del ADC. Esta colaboración amplía la presencia de Synaffix en la región de APAC y tiene como objetivo abordar áreas de altas necesidades médicas no satisfechas.
시나픽스는 론자의 자회사로, 미쓰비시 다나베 제약(MTPC)과 단일 ADC 프로그램 개발을 위한 라이센스 계약을 체결했습니다. 이 계약에는 효능, 내약성 및 표적 활성화를 향상시키기 위한 시나픽스의 독점 기술인 GlycoConnect®, HydraSpace® 및 toxSYN®의 사용이 포함됩니다.
계약 조건에 따라 시나픽스는 독점 기술과 관련된 구성요소를 제조하고, MTPC는 ADC의 연구, 개발, 제조 및 상용화를 책임지게 됩니다. 이번 협력은 시나픽스의 APAC 지역 내 입지를 확장하고, 높은 의료 수요 충족이 필요한 분야를 다루는 것을 목표로 합니다.
Synaffix, une société de Lonza, a signé un accord de licence avec Mitsubishi Tanabe Pharma (MTPC) pour le développement d'un programme ADC unique. Cet accord comprend l'utilisation des technologies ADC propriétaires de Synaffix, GlycoConnect®, HydraSpace® et toxSYN®, visant à améliorer l'efficacité, la tolérabilité et l'engagement cible.
Selon les termes de l'accord, Synaffix fabriquera les composants liés à ses technologies propriétaires, tandis que MTPC sera responsable de la recherche, du développement, de la fabrication et de la commercialisation de l'ADC. Cette collaboration élargit la présence de Synaffix dans la région APAC et vise à répondre à des besoins médicaux élevés non satisfaits.
Synaffix, ein Unternehmen von Lonza, hat einen Lizenzvertrag mit Mitsubishi Tanabe Pharma (MTPC) für die Entwicklung eines einzelnen ADC-Programms abgeschlossen. Der Vertrag umfasst die Nutzung der proprietären ADC-Technologien von Synaffix, GlycoConnect®, HydraSpace® und toxSYN®, die darauf abzielen, die Wirksamkeit, Verträglichkeit und Zielbindung zu verbessern.
Gemäß den Bedingungen des Vertrags wird Synaffix Komponenten im Zusammenhang mit seinen proprietären Technologien herstellen, während MTPC für Forschung, Entwicklung, Herstellung und Vermarktung des ADC verantwortlich sein wird. Diese Zusammenarbeit erweitert die Präsenz von Synaffix in der APAC-Region und zielt darauf ab, Bereiche mit hohem unbefriedigtem medizinischem Bedarf anzugehen.
- Strategic expansion into APAC market through partnership with major pharmaceutical company
- Revenue potential from manufacturing components for proprietary technologies
- Technology licensing deal with established pharma
- to single ADC program development
- Manufacturing responsibilities restricted to specific components only
- License agreement centered around development of a single ADC program
- Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement
Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.
Peter van de Sande, Head of Synaffix, said: "This latest licensing deal with MTPC highlights the appeal of our industry-leading ADC technology offering. MTPC is a key collaborator for us, expanding our presence in the APAC region, and we are excited to work alongside such a large and reputable corporation with the aim to make a tangible difference for patients in areas of high unmet medical need."
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.
The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its partner pipeline.
Synaffix was fully acquired by Lonza in June 2023.
For more information about Synaffix's ADC platform technology, please visit: https://synaffix.com/platform/technology/
About Lonza
Lonza is one of the world's largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from lifesaving and life-enhancing treatments.
Our business is structured to meet our customers' complex needs. Our company generated sales of
Follow @Lonza on LinkedIn
Follow @LonzaGroup on X
About Mitsubishi Tanabe Pharma Corporation (MTPC)
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi,
View original content:https://www.prnewswire.com/news-releases/synaffix-and-mitsubishi-tanabe-pharma-sign-license-agreement-for-adc-technology-302346911.html
SOURCE Synaffix B.V.
FAQ
What technologies are included in the Synaffix-MTPC ADC license agreement?
What are the responsibilities of Synaffix and MTPC in the ADC development agreement?
How many ADC programs are covered under the Synaffix-MTPC license agreement?
What is the strategic significance of the MTPC partnership for Synaffix?
